Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer.
Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...
Sun Pharmaceutical Industries Ltd. closed 14.48% below its 52-week high of 1,960.20 rupees, which the company reached on ...
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...
The New Jersey Economic Development Authority board March 12 approved $5.24 million in tax credits under the Emerge Program ...
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...
The NJEDA Board approved tax credits under the Emerge Program to support Sun Pharmaceutical Industries Inc.’s plan to open a new ...
Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
The country's top specialty generics company recently acquired US-based Checkpoint that will further its oncology portfolio ...
Sun Pharmaceutical Industries Ltd. closed 14.10% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.
Stay up-to-date with the Sun Pharma Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback